Trademark: AEGLEA 2201821
Word
AEGLEA
ID
2201821
Trademark Type
Word
Status
Protected: Registered/protected
Application Date
08 June 2021
Registration Date
08 June 2021
Renewal Date
08 June 2031
Owner(s)
Service
Gilbert + Tobin Lawyers
Goods and Services:
Class 5:
Pharmaceutical preparations for the treatment of rare genetic diseases; pharmaceutical preparations for the treatment of arginase 1 deficiency; pharmaceutical preparations for the treatment of cancer; biopharmaceutical preparations for the treatment of rare genetic diseases; biopharmaceutical preparations for the treatment of arginase 1 deficiency; biopharmaceutical preparations for the treatment of cancer; biotherapeutic preparations for the treatment of rare genetic diseases; biotherapeutic preparations for the treatment of arginase 1 deficiency; biotherapeutic preparations for the treatment of cancer; biotherapeutic preparations and substances for the treatment of rare genetic diseases; biotherapeutic preparations and substances for the treatment of arginase 1 deficiency; biotherapeutic preparations and substances for the treatment of cancer; enzyme replacement therapy preparations for medical purposes; pharmaceutical preparations for the prevention and treatment of infectious diseases and immunological diseases; biopharmaceutical preparations for the prevention and treatment of infectious diseases and immunological diseases; pharmaceutical preparations for the treatment of homocystinuria; biopharmaceutical preparations for the treatment of homocystinuria; biotherapeutic preparations for the treatment of homocystinuria.
Pharmaceutical preparations for the treatment of rare genetic diseases; pharmaceutical preparations for the treatment of arginase 1 deficiency; pharmaceutical preparations for the treatment of cancer; biopharmaceutical preparations for the treatment of rare genetic diseases; biopharmaceutical preparations for the treatment of arginase 1 deficiency; biopharmaceutical preparations for the treatment of cancer; biotherapeutic preparations for the treatment of rare genetic diseases; biotherapeutic preparations for the treatment of arginase 1 deficiency; biotherapeutic preparations for the treatment of cancer; biotherapeutic preparations and substances for the treatment of rare genetic diseases; biotherapeutic preparations and substances for the treatment of arginase 1 deficiency; biotherapeutic preparations and substances for the treatment of cancer; enzyme replacement therapy preparations for medical purposes; pharmaceutical preparations for the prevention and treatment of infectious diseases and immunological diseases; biopharmaceutical preparations for the prevention and treatment of infectious diseases and immunological diseases; pharmaceutical preparations for the treatment of homocystinuria; biopharmaceutical preparations for the treatment of homocystinuria; biotherapeutic preparations for the treatment of homocystinuria.
Class 42:
Scientific research in the fields of pharmaceuticals, biopharmaceuticals, medicine, biologics, biotherapeutics, biosimilars, enzyme replacement therapeutics, and therapeutics; medical and scientific research in the field of pharmaceutical and biopharmaceutical treatment of rare genetic diseases, arginase 1 deficiency, cancer, immunological diseases, homocystinuria, and infectious diseases; providing medical and scientific research information, consultancy, and advisory services, all in the fields of pharmaceuticals, biopharmaceuticals, medicine, biologics, biotherapeutics, biosimilars, enzyme replacement therapeutics, and therapeutics treatments; design, engineering, research, development and testing services in the fields of cancer, rare genetic disease, arginase 1 deficiency treatments, immunological diseases, homocystinuria, and infectious diseases.
Scientific research in the fields of pharmaceuticals, biopharmaceuticals, medicine, biologics, biotherapeutics, biosimilars, enzyme replacement therapeutics, and therapeutics; medical and scientific research in the field of pharmaceutical and biopharmaceutical treatment of rare genetic diseases, arginase 1 deficiency, cancer, immunological diseases, homocystinuria, and infectious diseases; providing medical and scientific research information, consultancy, and advisory services, all in the fields of pharmaceuticals, biopharmaceuticals, medicine, biologics, biotherapeutics, biosimilars, enzyme replacement therapeutics, and therapeutics treatments; design, engineering, research, development and testing services in the fields of cancer, rare genetic disease, arginase 1 deficiency treatments, immunological diseases, homocystinuria, and infectious diseases.